Welcome to our dedicated page for Zepp Health SEC filings (Ticker: ZEPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zepp Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zepp Health's regulatory disclosures and financial reporting.
Zepp Health Corp officer Pengtao Yu reported an intent to sell 20,000 ADSs for personal tax arrangements. The sale is expected in two batches: 10,000 ADSs in September 2026 and 10,000 in December 2026, in any event within three months after the September 23, 2026 notice. The securities description states that each ADR represents 16 Class A ordinary shares. The securities are associated with restricted share units granted under the issuer’s Share Incentive Plan, with vesting dates of May 28, 2020, and October 10, 2020.
Zepp Health Corp (ZEPP) reported unaudited second-quarter 2026 results showing modest top-line growth but continued losses. Revenue was US$63.5 million, up 6.9% year over year, helped by new products such as Active 3 Premium, Active Max and Cheetah. Gross margin improved to 37.4%, up 1.2 percentage points from a year earlier, mainly from a richer product mix despite higher memory costs and currency headwinds.
Operating expenses rose to US$36.0 million (GAAP), driven largely by increased selling and marketing spend and foreign-exchange impacts, leading to a wider operating loss of US$12.3 million and net loss attributable to Zepp of US$11.3 million, versus US$7.7 million a year ago. Cash, cash equivalents and restricted cash were US$106.3 million as of June 30, 2026, up from both a year earlier and March 31, 2026, supported by improved working-capital management and lower inventories.
Management guided third-quarter 2026 net revenues to US$68.0–73.0 million, below the prior-year quarter’s US$75.8 million due to a high comparison base and timing of production ramps and supply recovery, though they noted improving product mix and demand. Zepp has cumulatively retired US$40.2 million of debt since early 2023 and has repurchased US$17.6 million (approximately 2.4 million ADSs) under its share repurchase program.
Zepp Health Corp received an amended Schedule 13G/A indicating that Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen no longer report any beneficial ownership of the company’s Class A ordinary shares. As of the close of business on June 30, 2026, each reporting person lists 0.00 shares beneficially owned and 0% of the class, with no sole or shared voting or dispositive power. The position had been held in the form of American Depositary Shares quoted on the New York Stock Exchange under the symbol ZEPP.
Zepp Health Corporation’s large shareholder group consisting of Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed an amended Schedule 13G indicating they now report 0 Class A Ordinary Shares beneficially owned and 0.0% of this class.
The filing shows no sole or shared voting or dispositive power for any of these reporting persons. It also confirms they now hold 5 percent or less of Zepp Health’s Class A Ordinary Shares. The CUSIP 98945L204 applies to American Depositary Shares, with each ADS representing 16 Class A Ordinary Shares.
Morgan Stanley and Morgan Stanley Capital Services LLC report beneficial ownership of Zepp Health Corp Class A Ordinary Shares / American Depositary Receipts on an amended Schedule 13G. The firms report 11,869,344 shares with shared voting and shared dispositive power, representing 8.8% of the class as of June 30, 2026. They report no sole voting or dispositive power, and clarify that the filing only reflects holdings of specified Morgan Stanley reporting units, not all affiliates.
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC report beneficial ownership of 11,869,344 Class A ordinary shares / American Depositary Receipts of Zepp Health Corp, representing 8.8% of this class. Both entities report 0 shares with sole voting or dispositive power and 11,869,344 shares with shared voting and shared dispositive power. The filing is made on a joint basis by these Delaware-organized entities, with additional subsidiary details referenced in Exhibit 99.2 and a joint filing agreement in Exhibit 99.1.
FIL Limited, together with affiliated entities including Pandanus Partners, L.P. and Pandanus Associates, Inc., reports beneficial ownership of 11,490,848 shares of Zepp Health Corp Class A common stock on an amended Schedule 13G.
This position represents 8.5% of the outstanding Class A common stock as of June 30, 2026. FIL Limited reports sole voting power over 11,490,848 shares, while Pandanus entities report no voting power but sole dispositive power over the same number of shares. One or more other persons have rights to dividends or sale proceeds, but no such person holds more than five percent of the class.
Zepp Health Corp Chief Technology Officer Meihui Fan exercised options to acquire 520,000 Class A ordinary shares on June 26, 2026. These shares are held indirectly through Fandler Holding Limited, an entity ultimately owned by a trust established for the benefit of Mr. Fan and his family members.
Following the transactions, Fandler Holding Limited held 952,000 Class A ordinary shares. The filing shows multiple option grants, each with an exercise or conversion price of $0.0000 per share, being converted into Class A ordinary shares, with no reported share sales in this filing.
Zepp Health Corp’s Chief Financial Officer, Deng Cheng, reported compensation-related equity activity involving American depositary shares (ADSs) and restricted share units (RSUs). On June 26, 2026, 366,000 RSUs, each representing one Class A ordinary share, vested and were settled into ADSs, with each ADS representing 16 Class A ordinary shares. This conversion delivered 22,875 ADSs at no cost to the CFO.
On the same date, 9,836 ADSs were sold in the open market at a weighted average price of $4.61 per ADS in a sell-to-cover transaction to pay tax withholding obligations tied to the RSU vesting. Following these transactions, the CFO directly holds 114,539 ADSs, indicating that most of the vested equity was retained as ongoing ownership.
Zepp Health Corp Schedule 13G filing reports that Morgan Stanley (through reporting units) beneficially holds 8,472,224 Class A Ordinary Shares / ADRs, representing 7.5% of the class. The filing lists shared voting power of 8,472,128 and shared dispositive power of 8,472,224, and is signed by an authorized Morgan Stanley signatory.